ImpediMed Ltd
ASX:IPD
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
AU |
ImpediMed Ltd
ASX:IPD
|
159.8m AUD | -12.7 | ||
US |
Abbott Laboratories
NYSE:ABT
|
176.9B USD | 24.8 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
142B USD | 83.2 | ||
US |
Stryker Corp
NYSE:SYK
|
128.8B USD | 37.1 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
110.5B USD | 44.6 | ||
IE |
Medtronic PLC
NYSE:MDT
|
107.6B USD | 15.9 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
65.9B USD | 17.5 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
60.2B EUR | 31.2 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
52.3B USD | 58.4 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
50.4B USD | 62.9 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
360.9B CNY | 28.7 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.